H.C. Wainwright initiated coverage of Innoviva (INVA) with a Buy rating and $40 price target The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from “durable” royalty streams on mass market respiratory disease franchises.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva initiated with an Overweight at Cantor Fitzgerald
- Innoviva announces zoliflodacin NDA granted Priority Review by FDA
- Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin
- Innoviva Elects Board Members and Approves Compensation
- Innoviva subsidiary announces U.S. commercial availability of ZEVTERA